BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30779600)

  • 1. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
    Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
    J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
    Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
    Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
    J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
    J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
    Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival in metastatic germ-cell cancer.
    Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
    Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
    Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
    Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
    Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
    JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
    Hentrich M; Debole J; Jurinovic V; Gerl A
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
    Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
    Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center.
    Ataergin S; Ozet A; Arpaci F; Kilic S; Beyzadeoglu M; Komurcu S
    Indian J Cancer; 2007; 44(1):6-11. PubMed ID: 17401218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
    Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
    BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.
    Fedyanin M; Tryakin A; Bulanov A; Fainshtein I; Zakharova T; Matveev V; Garin A; Tjulandin S
    Urol Oncol; 2014 Jan; 32(1):32.e27-33. PubMed ID: 23628310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Dose Chemotherapy With Autologous Stem Cell Transplant for Patients With Advanced Germ Cell Tumors: Real-World Evidence From a Tertiary Cancer Center in Brazil.
    Polho GB; Cunha MT; Coelho MHM; Almeida-Silva J; Hidalgo Filho CM; Xavier EM; Crusoe NS; Atanazio MJ; de Vasconcellos VF; Horita VN; Freitas GF; Muniz DQ; Rocha V; Mota JM
    Clin Genitourin Cancer; 2024 Jun; 22(3):102083. PubMed ID: 38658209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
    Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
    Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.